24/7 Market News Snapshot 27 February, 2025 – Organogenesis Holdings Inc. Class A Common Stock (NASDAQ:ORGO)

February 27, 2025

DENVER, Colo., 27 February, 2025 (247marketnews.com) – (NASDAQ:ORGO) are discussed in this article.
Organogenesis Holdings Inc. (ORGO) has experienced a notable surge in its stock value, recently trading at $3.555, reflecting a significant gain of 9.38% following a day’s open at $3.25. This positive momentum is accompanied by a strong trading volume of 1.47 million shares, which underscores a robust investor interest, indicative of a bullish sentiment surrounding the company. Technical analysis suggests a prevailing upward trend, with potential resistance forming at approximately $3.60. Should ORGO sustain its trading above the $3.50 support level, it may signal prospects for continued growth. Investors are advised to keep an eye on market volume fluctuations and pertinent news developments as indicators of the trend’s resilience.

In parallel, Organogenesis has reported impressive financial results for the fourth quarter and the entire fiscal year ending December 31, 2024. The company achieved a substantial net revenue increase of 27% for the fourth quarter, reaching around $126.7 million compared to $99.7 million the previous year. This growth can be largely attributed to the Advanced Wound Care segment, which produced revenues of $118.6 million—a year-over-year rise of 27%. The Surgical & Sports Medicine sector also contributed positively, with revenue of $8.1 million representing a 24% increase.

Noteworthy financial metrics include a marked improvement in net income of $7.7 million in the fourth quarter, a stark contrast to the net loss of $0.6 million recorded the previous year. Furthermore, the adjusted EBITDA for the quarter surged by 143% to $18.2 million from $7.5 million in Q4 2023. For the fiscal year as a whole, Organogenesis saw total revenues of $482.0 million, an 11% increase compared to 2023, despite a slight decline in annual net income to $0.9 million. Looking ahead, CEO Gary S. Gillheeney, Sr. reaffirmed the company’s dedication to enhancing customer engagement and developing innovative solutions, with a major strategic milestone anticipated in 2025 through the BLA submission for ReNu, aimed at advancing treatment for knee osteoarthritis.

Related news for (ORGO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.